News Releases

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

Servier Expands Base4 Partnership to Advance Neuroscience Drug Development

Nicolas Garnier joins Servier as Chief Patient Officer

Servier Data at ASH 2023 Furthers Leadership in Hard-to-Treat Hematologic Malignancies

Data at ASH 2023 Underscores Servier Leadership in Hard-to-Treat Hematologic Malignancies

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

New Vorasidenib Data at SNO 2023 Bolster Servier's Neuro-Oncology Clinical Development Program

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)